Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression
Aβ34 is generated from degradation of Aβ40 and Aβ42 by β-secretase. Here, the authors show that Aβ34 is a marker for amyloid clearance and is elevated in the CSF of patients that go on to convert from mild cognitive impairment to Alzheimer’s disease, suggesting it may be a useful biomarker.
Guardado en:
Autores principales: | Filip Liebsch, Luka Kulic, Charlotte Teunissen, Adeola Shobo, Irem Ulku, Vivienne Engelschalt, Mark A. Hancock, Wiesje M. van der Flier, Peter Kunach, Pedro Rosa-Neto, Philip Scheltens, Judes Poirier, Paul Saftig, Randall J. Bateman, John Breitner, Christoph Hock, Gerhard Multhaup |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b145f3c2811a4f8c9097430d26ff9fe5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease
por: Elisabeth H. Thijssen, et al.
Publicado: (2021) -
The beta secretase BACE1 regulates the expression of insulin receptor in the liver
por: Paul J. Meakin, et al.
Publicado: (2018) -
Application of consensus scoring and principal component analysis for virtual screening against β-secretase (BACE-1).
por: Shu Liu, et al.
Publicado: (2012) -
Activation of PKR causes amyloid ß-peptide accumulation via de-repression of BACE1 expression.
por: Gerard Ill-Raga, et al.
Publicado: (2011) -
The anti-diabetic drug metformin reduces BACE1 protein level by interfering with the MID1 complex.
por: Moritz M Hettich, et al.
Publicado: (2014)